Shots:
- The P-II IXPLORE study involves assessing vilobelimab (400/800mg, q2w) + SOC vs PBO + SOC in 19 patients with ANCA associated vasculitis or AAV in the US
- The therapy is safe and well-tolerated in combination with SoC, clinical response & remission for each treatment group @16wks. was measured as 2EPs and showed 50% reduction in BVAS, patients in higher dose (800mg) showed BVAS (17.5mean / 16.5median), while 400mg dose showed (13.1 mean / 12.0 median) vs (13.8mean / 13.5median) with SOC group
- The results further support the continued study of vilobelimab for the treatment of AAV. Part 1 & 2 of the P-II IXCHANGE trial are fully enrolled in the EU, results are expected in the end of 2021
Click here to read full press release/ article | Ref: InflaRx | Image: InflaRx
The post InflaRx Reports Results of Vilobelimab in P- II IXPLORE Study in Patients with Anti-Neutrophil Cytoplasmic Autoantibody Associated Vasculitis first appeared on PharmaShots.
